Soley Bayraktar

Hematology | Oncology

9485 Mentor Ave Ste 3
Mentor, OH 44060

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.

Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer.

Journal: Future oncology (London, England)

Published: August 18, 2020

Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center.

Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center.

Journal: Turk gogus kalp damar cerrahisi dergisi

Published: July 24, 2020

Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.

Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.

Journal: The breast journal

Published: March 28, 2020

Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study.

Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study.

Journal: Cancer prevention research (Philadelphia, Pa.)

Published: February 27, 2020

Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer.

Journal: Journal of carcinogenesis

Published: October 15, 2019

Immunotherapy in breast cancer.

Immunotherapy in breast cancer.

Journal: Journal of carcinogenesis

Published: March 02, 2019

BRCA mutation genetic testing implications in the United States.

BRCA mutation genetic testing implications in the United States.

Journal: Breast (Edinburgh, Scotland)

Published: October 31, 2016

Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.

Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.

Journal: Biomarkers in cancer

Published: May 15, 2015

Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.

Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.

Journal: The breast journal

Published: March 20, 2015

Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.

Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.

Journal: Breast (Edinburgh, Scotland)

Published: May 09, 2014

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.

Journal: Medical oncology (Northwood, London, England)

Published: April 01, 2014

A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.

A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.

Journal: Cancer chemotherapy and pharmacology

Published: December 12, 2013

Showing 1-12 of 29

Last Updated: 09/26/2026